Loading...
Arrowhead Pharmaceuticals, Inc.
ARWR•NASDAQ
Healthcare
Biotechnology
$15.74
$-0.52(-3.20%)
Arrowhead Pharmaceuticals, Inc. (ARWR) Financial Performance & Income Statement Overview
Review Arrowhead Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-98.52%
↓ 98.52%
Operating Income Growth
-193.21%
↓ 193.21%
Net Income Growth
-192.04%
↓ 192.04%
Operating Cash Flow Growth
-200.77%
↓ 200.77%
Operating Margin
-21.74%
↓ 21.74%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-26.41%
↓ 26.41%
ROE
-46.00%
↓ 46.000%
ROIC
-8.76%
↓ 8.76%
Arrowhead Pharmaceuticals, Inc. (ARWR) Income Statement & Financial Overview
Review Arrowhead Pharmaceuticals, Inc.'s (ARWR) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.50M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $5.24M | $0.00 | $4.78M | $4.53M |
| Gross Profit | -$2.73M | $0.00 | -$4.78M | -$4.53M |
| Gross Profit Ratio | -$1.09 | $0.00 | ||
| R&D Expenses | $137.002M | $135.83M | $152.43M | $97.02M |
| SG&A Expenses | $26.40M | $25.79M | $23.20M | $24.64M |
| Operating Expenses | $163.91M | $162.20M | $176.14M | $121.67M |
| Total Costs & Expenses | $163.91M | $162.20M | $176.14M | $126.19M |
| Interest Income | $7.60M | $7.17M | $6.50M | $6.25M |
| Interest Expense | $21.65M | $14.65M | $5.09M | $7.24M |
| Depreciation & Amortization | $5.24M | $5.03M | $4.78M | $4.53M |
| EBITDA | -$148.23M | -$153.13M | -$164.10M | -$115.23M |
| EBITDA Ratio | -$59.29 | |||
| Operating Income | -$161.41M | -$162.20M | -$176.14M | -$126.19M |
| Operating Income Ratio | -$64.56 | |||
| Other Income/Expenses (Net) | -$13.70M | -$10.60M | $2.16M | -$805000.00 |
| Income Before Tax | -$175.12M | -$172.80M | -$173.98M | -$127.00M |
| Income Before Tax Ratio | -$70.05 | |||
| Income Tax Expense | $103000.00 | $546000.00 | $0.00 | -$1.70M |
| Net Income | -$173.09M | -$170.54M | -$170.79M | -$125.30M |
| Net Income Ratio | -$69.23 | |||
| EPS | -$1.39 | $0.00 | -$1.38 | -$1.02 |
| Diluted EPS | -$1.39 | $0.00 | -$1.38 | -$1.02 |
| Weighted Avg Shares Outstanding | $124.85M | $0.00 | $124.20M | $123.28M |
| Weighted Avg Shares Outstanding (Diluted) | $124.85M | $0.00 | $124.20M | $123.28M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan